arvac-cg
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Apr 20, 2022 (NCT05656508)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05752201 | Phase 2/Phase 3 (Phase 3) | Feb 6, 2023 | Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno, Laboratorio Pablo Cassará S.R.L., National Council of Scientific and Technical Research, Argentina, Universidad Nacional de San Martín (UNSAM) |
| NCT05656508 | Phase 1 | Apr 20, 2022 | Laboratorio Pablo Cassará S.R.L., National Council of Scientific and Technical Research, Argentina, Universidad Nacional de San Martín (UNSAM) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Laboratorio Pablo Cassará S.R.L. | For profit | 2 | 1 | 2 | 2022 |
| National Council of Scientific and Technical Research, Argentina | Academic/Hospital | 2 | 0 | 2 | 2022 |
| Universidad Nacional de San Martín (UNSAM) | Academic/Hospital | 2 | 0 | 2 | 2022 |
| Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno | Academic/Hospital | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1